All In Biotech

Drug Trial Radar · NCT05738850

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of ABBV-932 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jul 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

104

Actual

Start

Feb 15, 2023

Primary completion

May 31, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Gedeon Richter Plc.
First posted
Feb 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.

Conditions

  • Generalized Anxiety Disorder (GAD)
  • Healthy Participants

Interventions

  • ABBV-932Drug

    Oral Capsule

  • PlaceboDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of ABBV-932Time frame: Up to approximately 5 days
  2. Time to Cmax (Tmax) of ABBV-932Time frame: Up to approximately 5 days
  3. Terminal Phase Elimination Rate Constant (Beta) of ABBV-932Time frame: Up to approximately 5 days
  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-932Time frame: Up to approximately 5 days
  5. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932Time frame: Up to approximately 5 days
  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932Time frame: Up to approximately 5 days
  7. Maximum Plasma Concentration (Cmax) of DCARTime frame: Up to approximately 5 days
  8. Time to Cmax (Tmax) of DCARTime frame: Up to approximately 5 days
  9. Terminal Phase Elimination Rate Constant (Beta) of DCARTime frame: Up to approximately 5 days
  10. Terminal Phase Elimination Half-Life (t1/2) of DCARTime frame: Up to approximately 5 days
  11. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DCARTime frame: Up to approximately 5 days
  12. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DCARTime frame: Up to approximately 5 days
  13. Maximum Plasma Concentration (Cmax) of DDCARTime frame: Up to approximately 5 days
  14. Time to Cmax (Tmax) of DDCARTime frame: Up to approximately 5 days
  15. Terminal Phase Elimination Rate Constant (Beta) of DDCARTime frame: Up to approximately 5 days
  16. Terminal Phase Elimination Half-Life (t1/2) of DDCARTime frame: Up to approximately 5 days
  17. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of DDCARTime frame: Up to approximately 5 days
  18. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of DDCARTime frame: Up to approximately 5 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials LLC /ID# 254178

    Anaheim, California

  • Acpru /Id# 249639

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.